Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

USA resistance patterns among UTI pathogens

K S Thomson1, W E Sanders, C C Sanders

  • 1Creighton University School of Medicine, Omaha, Nebraska 68178.

The Journal of Antimicrobial Chemotherapy
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Clinical drug investigation·2016
Same author

In-vitro auxin binding to particulate cell fractions from corn coleoptiles.

Planta·2014
Same author

1-N-naphthylphthalamic acid and 2,3,5-triiodobenzoic acid : In-vitro binding to particulate cell fractions and action on auxin transport in corn coleoptiles.

Planta·2014
Same author

In-vitro binding of morphactins and 1-N-naphthylphthalamic acid in corn coleoptiles and their effects on auxin transport.

Planta·2014
Same author

Positive extended-spectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs.

Journal of clinical microbiology·2009
Same author

The role of the microbiology laboratory in an era of increasing antibiotic resistance.

Postgraduate medicine·2009
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Fluoroquinolone antibiotics are potent but resistance is growing. Limiting their use for urinary tract infections can conserve their effectiveness and reduce costs.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Fluoroquinolones represent a potent class of broad-spectrum antimicrobials widely used in the United States.
  • Antimicrobial resistance to fluoroquinolones is emerging in various bacterial species, including Staphylococcus spp., Pseudomonas spp., and Enterobacteriaceae.
  • Conserving the efficacy of fluoroquinolones is crucial due to their broad-spectrum activity.

Purpose of the Study:

  • To evaluate the necessity of routine fluoroquinolone use in treating urinary tract infections (UTIs).
  • To explore strategies for minimizing antimicrobial resistance development.
  • To assess the economic implications and therapeutic alternatives for UTIs.

Main Methods:

  • Review of current antimicrobial prescribing practices for UTIs.

Related Experiment Videos

  • Analysis of bacterial susceptibility patterns to fluoroquinolones and alternative agents.
  • Comparative efficacy and cost-effectiveness assessment of different UTI treatment options.

    • Main Results:

    • Fluoroquinolone resistance is developing in key bacterial pathogens.
    • Alternative oral antimicrobials like nitrofurantoin, co-trimoxazole, sulphonamides, and amoxycillin are effective for UTIs.
    • Significant cost savings can be achieved by using older, less expensive agents.

    Conclusions:

    • Routine use of fluoroquinolones for UTIs is generally not justified due to resistance concerns and available alternatives.
    • Restricting fluoroquinolone use, particularly in UTIs, is a key strategy to preserve their clinical utility.
    • Non-fluoroquinolone agents should be prioritized for UTI treatment unless specific contraindications exist.